Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 20/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 15/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 13/20 | 0.51 |
| ▸ | HTR2A | P28223 | 5/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9121785 | 0.69 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3HTR2AKCNH2 | |
| SCHEMBL6151910 | 0.68 | SLC6A4 (0.57) | SLC6A4SLC6A2SLC6A3HTR2AKCNH2 | |
| SCHEMBL6153377 | 0.64 | SLC6A4 (0.51) | SLC6A4SLC6A2SLC6A3HTR2AKCNH2 | |
| SCHEMBL6151177 | 0.64 | SLC6A4 (0.51) | SLC6A4SLC6A2SLC6A3HTR2AKCNH2 | |
| SCHEMBL6152457 | 0.64 | SLC6A4 (0.54) | SLC6A4SLC6A2SLC6A3HTR2AKCNH2 | |
| SCHEMBL5837316 | 0.60 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3HTR2AKCNH2 | |
| Hydrochloric Acid SCHEMBL5878972 | 0.59 | SLC6A4 (0.60) | SLC6A4SLC6A2SLC6A3HTR2AKCNH2 | |
| SCHEMBL11576617 | 0.59 | SLC6A4 (0.65) | SLC6A4SLC6A2SLC6A3HTR2AKCNH2 | |
| SCHEMBL6946976 | 0.59 | SLC6A4 (0.72) | SLC6A4SLC6A2SLC6A3HTR2AKCNH2 | |
| SCHEMBL5837104 | 0.59 | SLC6A4 (0.74) | SLC6A4SLC6A2SLC6A3HTR2AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020147206-A1 | Combination treatment of multiple sclerosis (MS), other demyelinating conditions and peripheral neuropathy, especially painful neuropathies and diabetic neuropathy | PFIZER INC. | 2002-10-10 | — | — | US | claimed |
| US-20020099045-A1 | Combination treatment for depression | PFIZER PRODUCTS INC. | 2002-07-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099045-A1 | Combination treatment for depression | HTR5A, HTR1A, OPRL1 | SLC6A4 11/4885SLC6A2 18/4885SLC6A3 53/4885 |
| US-20020147206-A1 | Combination treatment of multiple sclerosis (MS), other demyelinating conditions and peripheral neuropathy, especially painful neuropathies and diabetic neuropathy | PMP22, GAP43, SLC6A2 | SLC6A4 4/4885SLC6A2 3/4885SLC6A3 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.